skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Incorrect description of mode of excretion of linagliptin

Other

(1924) Views  (500) Full article downloads

Authors: Hans-Juergen Woerle, Sanjay Patel

Published Date June 2010 Volume 2010:2 Pages 93 - 94
DOI: http://dx.doi.org/10.2147/DHPS.S10440

Hans-Juergen Woerle, Sanjay Patel

Boehringer Ingelheim GmbH, Germany

Dear Dr Zhou,

Boehringer Ingelheim, owner of the investigational drug linagliptin, would like to point out that in the recent review paper by Cox and colleagues,1 titled “Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy”, which was published in Drug, Healthcare and Patient Safety, the authors have incorrectly described the mode of excretion for linagliptin as being predominantly renal. The correct statement should have read: “Excretion of linagliptin is predominantly nonrenal”, as described in the referenced pharmacokinetic study performed by Heise and colleagues.2 A nonrenal elimination route may be important in patients with renal impairment, which is common in patients with type 2 diabetes, so this distinction may be of clinical relevance. We would be grateful if you could clarify this for your readership to help avoid any confusion.








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio